Literature DB >> 25332440

Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.

Walter Jentzen1, Jan Hoppenbrouwers2, Paul van Leeuwen2, Daan van der Velden2, Rudie van de Kolk2, Thorsten Dirk Poeppel3, James Nagarajah3, Wolfgang Brandau3, Andreas Bockisch3, Sandra Rosenbaum-Krumme3.   

Abstract

UNLABELLED: (124)I PET/CT images from differentiated thyroid cancer patients were retrospectively analyzed to assess the relationship between absorbed radiation dose (AD) to lesions and their response after radioiodine therapy.
METHODS: Patients received serial (124)I PET/CT scans before and after their first radioiodine treatment. The pretherapy PET data were used to segment the lesion volumes and to predict the therapy-delivered ADs after administration of the therapeutic (131)I activity. The segmentation method's lower volume limit of determinability was a sphere of 0.80 mL, which classified the lesions into a known-volume group (>0.80 mL) or a small-volume group (≤0.80 mL) with their respective average and minimum ADs. The posttherapy PET data were used to assess the lesion-based therapy success. In the known-volume group, the response rate was calculated on the basis of lesions that received average ADs above the generally accepted threshold of 85 Gy for metastases and 300 Gy for thyroid remnants (TRs) and was expressed as the percentage of completely responding lesions. In the small-volume group, the metastasis and TR responses were evaluated for 3 minimum-AD groups: 5 to 10 Gy (TR, 5 to 30 Gy), >10 to 85 Gy (TR, >30 to 300 Gy), and >85 Gy (TR, >300 Gy). Their response rates were calculated in terms of the percentage of completely responding lesions in each minimum-AD group.
RESULTS: In total, 59 lesions in 17 patients were amenable to reliable volume estimation. The response rates were 63%, 88%, and 90% for lymph node metastases (LMs), pulmonary metastases, and TRs, respectively. The response rates of 168 small lesions in 34 patients were more than 82% for LMs and more than 91% for TRs in each of the 3 minimum-AD groups; all small pulmonary metastases responded completely.
CONCLUSION: In the known-volume group, the response rate for TRs matched well with historical data derived using (131)I scintigraphy imaging, whereas the response rate for LMs was not as high as expected, which may be explained by too short a follow-up time for a few LMs and a higher sensitivity of PET imaging. Small lesions were treated effectively, suggesting that they are considerably smaller than 0.80 mL.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  124I; dosimetry; radioiodine therapy; thyroid carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25332440     DOI: 10.2967/jnumed.114.144089

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.

Authors:  Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-16       Impact factor: 9.236

2.  Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.

Authors:  Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06       Impact factor: 9.236

Review 3.  Novel Approaches to Thyroid Cancer Treatment and Response Assessment.

Authors:  Ravinder K Grewal; Alan Ho; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

4.  Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?

Authors:  I Binse; T D Poeppel; M Ruhlmann; B Gomez; L Umutlu; A Bockisch; S J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-19       Impact factor: 9.236

5.  Intra-Individual Comparison of 124I-PET/CT and 124I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation Correction.

Authors:  Hong Grafe; Maike E Lindemann; Manuel Weber; Julian Kirchner; Ina Binse; Lale Umutlu; Ken Herrmann; Harald H Quick
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

6.  Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.

Authors:  Amir Sabet; Ina Binse; Hong Grafe; Samer Ezziddin; Rainer Görges; Thorsten D Poeppel; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236

7.  Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.

Authors:  Seong Young Kwon; Sang-Woo Lee; Eun Jung Kong; Keunyoung Kim; Byung Il Kim; Jahae Kim; Heeyoung Kim; Seol Hoon Park; Jisun Park; Hye Lim Park; So Won Oh; Kyoung Sook Won; Young Hoon Ryu; Joon-Kee Yoon; Soo Jin Lee; Jong Jin Lee; Ari Chong; Young Jin Jeong; Ju Hye Jeong; Young Seok Cho; Arthur Cho; Gi Jeong Cheon; Eun Kyoung Choi; Jae Pil Hwang; Sang Kyun Bae
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-10       Impact factor: 9.236

8.  I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response.

Authors:  Donika Plyku; Robert F Hobbs; Di Wu; Carlos Garcia; George Sgouros; Douglas Van Nostrand
Journal:  Ann Nucl Med       Date:  2022-02-04       Impact factor: 2.668

9.  Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference.

Authors:  Walter Jentzen; Jinda Phaosricharoen; Benedikt Gomez; Philipp Hetkamp; Vanessa Stebner; Ina Binse; Sonja Kinner; Ken Herrmann; Amir Sabet; James Nagarajah
Journal:  EJNMMI Phys       Date:  2018-07-19

10.  Calibration of PET/CT scanners for multicenter studies on differentiated thyroid cancer with (124)I.

Authors:  Jakob W Kist; Manfred van der Vlies; Otto S Hoekstra; Henri N J M Greuter; Bart de Keizer; Marcel P M Stokkel; Wouter V Vogel; Marc C Huisman; Arthur van Lingen
Journal:  EJNMMI Res       Date:  2016-04-27       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.